February #44 : New Drug Watch - by Tim Horn

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents

They Shoot Barebackers, Don't They?

A Ride on the Wild Side

Secrets & Lies

Brain Drain

All in the Family

Is Stoning Next?

Tee'd Off

Say What

Heart to HAART

S.O.S.

To the Editor

POZarazzi: Stardust Memories

Tee'd Off

Say What

The Stiles Files

You've Got Mail!

Ad of the Month: Oh, Good Lords!

Cry Cannabis

An Affair to Remember

Techno Truth

POZ Planet: Vital Stats

Behind the Eight Ball

Voter Fraud

Show & Tell

POZ Picks

Northern Disclosure

The Wizard of Roz

Obits

Heart to HAART

Ever Laughter

A River Ran Through Him

One Toke Over the Line

Talk Therapy

New Drug Watch

The Party’s Still On

The “No Nukes” Movement

Vits Help the Rits Go Down

Female Trouble

Not My Type

Where to Find It

Big Daddy

Aunt Evelyn's Letters

Verse: Eulogy for Brad



Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


email print

February 1999

New Drug Watch

by Tim Horn

A new nuke, a gen-two protease and more

Drug/Company: Abacavir (Ziagen)/Glaxo Wellcome
For: HIV
Status: Approved by the FDA last November
Standard Treatment: Highly active antiretroviral therapy (HAART)
Notes: A nucleoside analogue, or “nuke” (like AZT and 3TC). Abacavir combined with two other nukes seems as effective (in the treatment naive) as protease combos, at least for 24 weeks. Dangerous hypersensitivity (rash, fever) that precludes taking it again is possible.
From the gut of PWA Stephen Gendin: "How best to use abacavir is unclear. It has limited efficacy for the treatment-experienced, so you’ll probably have no option but to use it as part of your first combo.”

Drug/Company: ABT-378/Abbott Laboratories
For: HIV
Status: Phase II trials under way
Standard Treatment: HAART
Notes: The first “second generation” protease inhibitor in development, ABT-378 shows signs of a unique resistance profile (it is active against ritonavir [Norvir]-resistant HIV) and, when combined with a very low dose of ritonavir, the drug may only need to be taken once a day.
From the gut of PWA Stephen Gendin: “I’m anxiously awaiting this drug for my own use. Still, caution is in order since claims of unique resistance profiles are as common as they are overstated.”

Drug/Company: Pentafuside (T-20)/Trimeris, Inc.
For: HIV
Status: Phase II trials under way
Standard Treatment: HAART
Notes: A fusion inhibitor, pentafuside prevents HIV from “fusing” with, and infecting, CD4 cells. In one 12-person study, PWAs taking 100 mg twice daily without other drugs had a 1.5-log reduction in viral load and a 52 CD4-cell increase after 14 days. Infused automatically by portable pump.
From the gut of PWA Stephen Gendin: “Finally, a new class of drug that could work for everyone, regardless of antiretroviral history. The drawback: Pentafuside needs to be infused.”

Drug/Company: Cidofovir gel (Forvade)/Gilead Sciences
For: Herpes simplex
Status: Compassionate-use program; New Drug Application filed
Standard Treatment: Acyclovir; valacyclovir, famciclovir
Notes: Approximately half of PWAs using this topical drug had either a complete or a partial response in their herpes lesions after 15 days; all PWAs enrolled in this study had been unresponsive to previous therapy with acyclovir.
From the gut of PWA Stephen Gendin: “Herpes can get out of control in people with HIV, so more treatments are desperately needed. This gel is definitely worth watching.”




[Go to top]

Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV 101
HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
Disclosing Your Status
Starting Treatment
Search for the Cure
POZ Stories
POZ TV
Read the Blogs
Visit the Forums
Women
African American
Latino
Providers
Job Listings
Events Calendar


    charliehunter
    San Francisco
    California


    koffeeboss
    Tucson
    Arizona


    Heartland4now
    Tacoma
    Washington


    donnyp
    liberty
    Kentucky
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Can social media help stop HIV stigma?
Yes
No

Survey
Mind Matters

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.